Which complication is commonly monitored in patients receiving LMWH?

Monitoring platelet levels in patients receiving low molecular weight heparin (LMWH) is crucial because of the potential risk of heparin-induced thrombocytopenia (HIT). HIT is an adverse reaction characterized by a decrease in platelet count, which can lead to an increased risk of thrombosis instead of the desired anticoagulant effect.

Patients receiving LMWH require regular monitoring of their platelet levels to detect any significant drops early on, allowing for prompt management and prevention of thrombotic complications associated with HIT. Notably, although other laboratory values might be of interest in specific clinical circumstances or for different treatments, platelet monitoring is particularly relevant in the context of LMWH administration due to the specific risks associated with this anticoagulant therapy.